Profiel
Dean Hakanson held several positions in the healthcare industry, including Vice President-Healthcare Access at Bristol Myers Squibb Co., Head-Payer Field Team at Genentech, Inc., Vice President & Head-Medical Western US Region at Novartis AG, Vice President-Medical Affairs at GSK Plc, Chief Medical Officer at Otonomy, Inc., and VP-Medical Affairs Commercial Operations at National Accounts, Inc. He received an undergraduate degree from the University of Denver and a doctorate from The University of Colorado School of Medicine.
Eerdere bekende functies van Dean Hakanson
| Bedrijven | Functie | Einde |
|---|---|---|
| OTONOMY | Hoofd Techniek/Wetenschap/O&O | 31-01-2018 |
| NOVARTIS AG | Corporate Officer/Principal | 01-05-2010 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01-07-2009 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01-01-2008 |
| GSK PLC | Hoofd Techniek/Wetenschap/O&O | 01-01-2005 |
Opleiding van Dean Hakanson
| University of Denver | Undergraduate Degree |
| The University of Colorado School of Medicine | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| GSK PLC | Health Technology |
| NOVARTIS AG | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Otonomy, Inc.
 Otonomy, Inc. BiotechnologyHealth Technology Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm’s product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
| National Accounts, Inc. |
